SCHEMBL6623906

SCHEMBL6623906

O=C(Cc1sccc1NS(=O)(=O)c1ccc(-c2ccccc2)cc1)N1CCSCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ ACLY P53396 2/20 0.40
▸ MCL1 Q07820 2/20 0.39
▸ BCL2A1 Q16548 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ UQCRB P14927 2/20 0.38
▸ MMP1 P03956 2/20 0.38
▸ MMP12 P39900 2/20 0.38
▸ MMP2 P08253 2/20 0.38
▸ BCL2 P10415 1/20 0.37
▸ BCL2L1 Q07817 1/20 0.37
▸ BCL2L2 Q92843 1/20 0.37
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610858 0.91 GAA (0.48) GAAMAPTMEN1KMT2AMAPK1
SCHEMBL6623416 0.89 MAPT (0.53) GAAMAPTMEN1KMT2AMAPK1
SCHEMBL6624267 0.84 ALDH1A1 (0.43) GAAMAPTMEN1KMT2AMAPK1
SCHEMBL6614229 0.81 GAA (0.43) GAAMAPTMEN1KMT2AMAPK1
SCHEMBL6695816 0.80 LMNA (0.45) GAAMAPTKMT2AMAPK1
SCHEMBL6626083 0.79 ALDH1A1 (0.41) GAAMAPTMEN1KMT2AMAPK1
SCHEMBL6627797 0.78 SMN1; SMN2 (0.48) GAAMAPTKMT2AHTTHSD17B10
SCHEMBL6628476 0.78 ALDH1A1 (0.41) GAAMAPTKMT2AMAPK1HTT
SCHEMBL6625639 0.78 HDAC1 (0.46) GAAMAPTKMT2AMAPK1ACLY
SCHEMBL6628164 0.78 RAB9A (0.44) GAAMAPTMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 — — EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 — — WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 — — EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 GAA 351/4885MAPT 3254/4885MEN1 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback